These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 28408884)

  • 1. Effect of
    Liu S; Shi X; Tian X; Zhang X; Sun Z; Miao L
    Front Pharmacol; 2017; 8():176. PubMed ID: 28408884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics and pharmacodynamics of ticagrelor and AR-C124910XX in Chinese healthy male subjects.
    Liu S; Xue L; Shi X; Sun Z; Zhu Z; Zhang X; Tian X
    Eur J Clin Pharmacol; 2018 Jun; 74(6):745-754. PubMed ID: 29442148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No Effect of SLCO1B1 and CYP3A4/5 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Male Subjects.
    Li M; Hu Y; Li H; Wen Z; Hu X; Zhang D; Zhang Y; Xiao J; Tang J; Chen X
    Biol Pharm Bull; 2017; 40(1):88-96. PubMed ID: 28049954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP3A4*22 Impairs the Elimination of Ticagrelor, But Has No Significant Effect on the Bioactivation of Clopidogrel or Prasugrel.
    Holmberg MT; Tornio A; Paile-Hyvärinen M; Tarkiainen EK; Neuvonen M; Neuvonen PJ; Backman JT; Niemi M
    Clin Pharmacol Ther; 2019 Feb; 105(2):448-457. PubMed ID: 29998574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of CYP3A4*1G and CYP3A5*3 polymorphisms on pharmacokinetics of tylerdipine hydrochloride in healthy Chinese subjects.
    Zhou S; Tao M; Wang Y; Wang L; Xie L; Chen J; Zhao Y; Liu Y; Zhang H; Ou N; Wang G; Shao F; Aa J
    Xenobiotica; 2019 Mar; 49(3):375-380. PubMed ID: 29521134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.
    Zuo XC; Ng CM; Barrett JS; Luo AJ; Zhang BK; Deng CH; Xi LY; Cheng K; Ming YZ; Yang GP; Pei Q; Zhu LJ; Yuan H; Liao HQ; Ding JJ; Wu D; Zhou YN; Jing NN; Huang ZJ
    Pharmacogenet Genomics; 2013 May; 23(5):251-61. PubMed ID: 23459029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects.
    Teng R; Butler K
    Eur J Clin Pharmacol; 2010 May; 66(5):487-96. PubMed ID: 20091161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of PEAR1 rs12041331 polymorphism and pharmacodynamics of ticagrelor in healthy Chinese volunteers.
    Li M; Hu Y; Wen Z; Li H; Hu X; Zhang Y; Zhang Z; Xiao J; Tang J; Chen X
    Xenobiotica; 2017 Dec; 47(12):1130-1138. PubMed ID: 27937053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Sirolimus in Healthy Chinese Volunteers.
    Zhang J; Dai Y; Liu Z; Zhang M; Li C; Chen D; Song H
    Ther Drug Monit; 2017 Aug; 39(4):406-411. PubMed ID: 28700521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of CYP3A4*1G, CYP3A5*3, POR*28, and ABCB1 C3435T on the pharmacokinetics of nifedipine in healthy Chinese volunteers.
    Wang XF; Yan L; Cao HM; Wei LM; Yang WH; Zhang SJ; Zhang LR
    Int J Clin Pharmacol Ther; 2015 Sep; 53(9):737-45. PubMed ID: 26104034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of
    Nie S; Chen K; Guo C; Pei Q; Zou C; Yao L; Yuan H; Zhao X; Xie R; He X; Huang J; Yang G
    Front Pharmacol; 2021; 12():797278. PubMed ID: 35280252
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of genetic variations on ticagrelor plasma levels and clinical outcomes.
    Varenhorst C; Eriksson N; Johansson Å; Barratt BJ; Hagström E; Åkerblom A; Syvänen AC; Becker RC; James SK; Katus HA; Husted S; Steg PG; Siegbahn A; Voora D; Teng R; Storey RF; Wallentin L;
    Eur Heart J; 2015 Aug; 36(29):1901-12. PubMed ID: 25935875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of gene polymorphism on ticagrelor metabolism: an
    Hu X; Wang P; Zeng D; Hu GX
    PeerJ; 2024; 12():e18109. PubMed ID: 39346054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction
.
    Röshammar D; Bergstrand M; Andersson T; Storey RF; Hamrén B
    Int J Clin Pharmacol Ther; 2017 May; 55(5):416-424. PubMed ID: 28139972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects.
    Teng R; Oliver S; Hayes MA; Butler K
    Drug Metab Dispos; 2010 Sep; 38(9):1514-21. PubMed ID: 20551239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of food and gender on pharmacokinetics of ticagrelor and its main active metabolite AR-C124910XX in healthy Chinese subjects
.
    Feng W; Liu D; Wang Y; Shi X; Liu F; Sun L; Ding L
    Int J Clin Pharmacol Ther; 2018 Aug; 56(8):372-380. PubMed ID: 29932414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic study to evaluate the safety of ticagrelor combined with aspirin in the treatment of PCI patients in Chinese population: A single nucleotide polymorphisms study.
    Zheng S; Xu Y; Jie Q; Mu H; Zhang X; Zhu J; Zhu Y; Chen X; Chen S
    Drug Metab Pharmacokinet; 2023 Dec; 53():100468. PubMed ID: 38029471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients.
    Miura M; Satoh S; Kagaya H; Saito M; Numakura K; Tsuchiya N; Habuchi T
    Pharmacogenomics; 2011 Jul; 12(7):977-84. PubMed ID: 21635144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with mild hepatic impairment.
    Butler K; Teng R
    J Clin Pharmacol; 2011 Jul; 51(7):978-87. PubMed ID: 20926753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.